The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization

Pipa-Muñiz, María; Sanmartino, Susana; Mesa, Alicia; Álvarez-Navascués, Carmen; González-Diéguez, Maria-Luisa; Cadahía, Valle; Rodríguez, José-Eduardo; Vega, Florentino; Rodríguez, Manuel; Costilla-García, Serafin-Marcos; Varela, María

doi:10.1186/s12876-020-01307-x

Table 2 Predictors of overall survival from DEB-TACE-1 (period t₀) with pre-DEB-TACE variables (n = 216) based on multivariate Cox regression

From: The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization

T₀			Univariate analysis			Multivariate analysis
Variable	Categories	n = 216	Overall survival (months)		p-value	HR	HR 95% CI	p-value
Variable	Categories	n = 216	median	median 95% CI	p-value	HR	HR 95% CI	p-value
Esophageal varices	No varices	72	30	22.7–37.2	0.025
Esophageal varices	Varices	131	25	21.2–28.8	0.025
> 3 nodules	No	180	27	23.8–30.2	0.029
> 3 nodules	Yes	33	23	18.6–27.4	0.029
Tumor size^b(mm)	< 36.5	128	30	26.9–33.1	0.025	0.72	0.53–0.98	0.039
Tumor size^b(mm)	> 36.5	84	22	17.5–26.5	0.025	0.72	0.53–0.98	0.039
AFP pre-TACE ^a (ng/mL)	< 12.8	105	30	25.8–34.2	0.008
AFP pre-TACE ^a (ng/mL)	> 12.8	105	23	19.2–26.8	0.008
AFP pre-TACE (ng/mL)	< 100	165	29	26.1–31.8	0.009	0.67	0.47–0.96	0.029
AFP pre-TACE (ng/mL)	> 100	44	18	13.4–22.6	0.009	0.67	0.47–0.96	0.029
AFP pre-TACE (ng/mL)	< 200	181	29	26.5–31.5	< 0.001
AFP pre-TACE (ng/mL)	> 200	28	15	11.1–18.9	< 0.001
AFP pre-TACE (ng/mL)	< 400	192	28	25.2–30.8	0.002
AFP pre-TACE (ng/mL)	> 400	17	13	8.2–17.8	0.002
Bil pre-TACE ^a (mg/dL)	< 1	130	28	24.2–31.8	0.052
Bil pre-TACE ^a (mg/dL)	> 1	79	25	21.3–28.7	0.052
Bil pre-TACE (mg/dL)	< 2	191	27	23.8–30.1	0.47
Bil pre-TACE (mg/dL)	> 2	17	27	23.1–30.9	0.47
Alb pre-TACE ^a (g/L)	< 40	110	24	20.3–27.3	0.112
Alb pre-TACE ^a (g/L)	> 40	98	28	24.34–31.6	0.112
Alb pre-TACE (g/L)	< 35	39	23	18.6–27.4	0.021
Alb pre-TACE (g/L)	> 35	169	29	25.9–32.04	0.021
AP preTACE^a(IU/L)	< 108	105	32	28.01–35.9	< 0.001	0.64	0.47–0.88	0.005
AP preTACE^a(IU/L)	> 108	105	24	20.8–27.2	< 0.001	0.64	0.47–0.88	0.005
Hb pre-TACE^a (g/dL)	< 13.6	108	24	19.02–28.9	0.155
Hb pre-TACE^a (g/dL)	> 13.6	105	28	25.6–30.3	0.155
Platelets preTACE, 10^{^9} / L	< 100	90	26	22.3–29.6	0.93
Platelets preTACE, 10^{^9} / L	> 100	121	27	22.7–31.2	0.93
Ascites preTACE	No	198	27	24.4–29.6	0.068
Ascites preTACE	Yes	18	21	16.9–25.01	0.068
CSPH	No	59	30	22.5–37.5	0.045
CSPH	Yes	157	26	22.3–29.7	0.045

CI Confidence interval, HR Hazard ratio, TACE Transarterial chemoembolization, BCLC Barcelona Clinic Liver Cancer, CSPH Clinically significant portal hypertension., AFP Alpha-fetoprotein, Bil Bilirubin, Alb Albumin, AP Alkaline phosphatase, Hb Hemoglobin
^aThe median values were used as a cut-off for continuous variables. ^b Tumor size estimated by AUROC
Other variables evaluated: sex (p = 0.156), etiology (0.197); diabetes (p = 0.929); AST (p = 0.340); ALT (p = 0.791); GGT (p = 0.289); Creatinine (p = 0.847); Na (p = 0.944); CBCT use (p = 0.495); DEB size (p = 0.283)

Back to article page

ISSN: 1471-230X

Contact us

Submission enquiries: bmcgastroenterology@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Gastroenterology

Contact us